In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency ...

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...

Baseline circulating tumor cell count “may serve as a valuable, noninvasive biomarker” for patients with metastatic hormone-sensitive prostate cancer, according to researchers.

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

The sNDA is seeking approval of darolutamide, in combination with androgen deprivation therapy (ADT), in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Darolutamide is an oral ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

The Israeli military confirmed that Yahya Sinwar, the leader of Hamas, was killed on Wednesday. Prime Minister Benjamin Netanyahu of Israel said he spoke with President Biden about working to ...